Sfoglia per Autore
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis
2011-01-01 Talamonti, M; Galluzzo, M; Teoli, M; Bavetta, M; Chimenti, S; Costanzo, A
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome
2012-01-01 Talamonti, M; Galluzzo, M; Chiricozzi, A; Teoli, M; Bavetta, M; Costanzo, A; Chimenti, S
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis
2012-09-01 Botti, E; Talamonti, M; Spallone, G; Galluzzo, M; Bavetta, M; Teoli, M; Pinetti, V; Costanzo, A
Genetic variations in IL6 and IL12B as protective markers for psoriasis
2013-01-01 Boca, An; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, Ad; Costanzo, A
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris
2013-01-01 Di Stefani, A; Galluzzo, M; Talamonti, M; Chiricozzi, A; Costanzo, A; Chimenti, S
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases
2013-01-01 Saraceno, R; Talamonti, M; Galluzzo, M; Chiricozzi, A; Costanzo, A; Chimenti, S
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis
2013-01-01 Boca, An; Talamonti, M; Galluzzo, M; Botti, E; Vesa, Tc; Chimenti, S; Buzoianu, Ad; Costanzo, A
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients
2013-01-01 Talamonti, M; Galluzzo, M; Botti, E; Pavlidis, A; Spallone, G; Chimenti, S; Costanzo, A
Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom
2013-05-01 Boca, A; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, A; Costanzo., A
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab
2013-08-01 Talamonti, M; Botti, E; Galluzzo, M; Teoli, M; Spallone, G; Bavetta, M; Chimenti, S; Costanzo, A
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment
2014-01-01 Talamonti, M; Galluzzo, M; Botti, E; Chimenti, S; Costanzo, A
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice
2014-01-01 Talamonti, M; Galluzzo, M; Bianchi, L; Boca, A; Costanzo, A; Chimenti, S
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature
2015-01-01 Chimenti, Ms; Talamonti, M; Novelli, L; Teoli, M; Galluzzo, M; Triggianese, P; Perricone, R
Linear psoriasis following the typical distribution of the sciatic nerve
2015-01-01 Galluzzo, M; Talamonti, M; Di Stefani, A; Chimenti, S
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients
2015-01-01 Talamonti, M; Galluzzo, M; Botti, E; Costanzo, A; Chimenti, S
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis
2016-01-01 Talamonti, M; Galluzzo, M; Chimenti, S; Costanzo, A
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up
2016-01-01 Talamonti, M; Galluzzo, M; Chimenti, S; Costanzo, A
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis
2016-01-01 Galluzzo, M; Boca, An; Botti, E; Potenza, C; Malara, G; Malagoli, P; Vesa, S; Chimenti, S; Buzoianu, Ad; Talamonti, M; Costanzo, A
Tofacitinib for the treatment of psoriasis
2016-01-01 Galluzzo, M; D'Adamio, S; Servoli, S; Bianchi, L; Chimenti, S; Talamonti, M
Brodalumab for the treatment of psoriasis
2016-01-01 Galluzzo, M; D'Adamio, S; Bianchi, L; Talamonti, M
Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
---|---|---|---|---|
1-gen-2011 | Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis | Talamonti, M; Galluzzo, M; Teoli, M; Bavetta, M; Chimenti, S; Costanzo, A | Intervento a convegno | |
1-gen-2012 | Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome | Talamonti, M; Galluzzo, M; Chiricozzi, A; Teoli, M; Bavetta, M; Costanzo, A; Chimenti, S | Articolo su rivista | |
1-set-2012 | Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis | Botti, E; Talamonti, M; Spallone, G; Galluzzo, M; Bavetta, M; Teoli, M; Pinetti, V; Costanzo, A | Intervento a convegno | |
1-gen-2013 | Genetic variations in IL6 and IL12B as protective markers for psoriasis | Boca, An; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, Ad; Costanzo, A | Intervento a convegno | |
1-gen-2013 | Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris | Di Stefani, A; Galluzzo, M; Talamonti, M; Chiricozzi, A; Costanzo, A; Chimenti, S | Articolo su rivista | |
1-gen-2013 | Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases | Saraceno, R; Talamonti, M; Galluzzo, M; Chiricozzi, A; Costanzo, A; Chimenti, S | Articolo su rivista | |
1-gen-2013 | Genetic variations in IL6 and IL12B decreasing the risk for psoriasis | Boca, An; Talamonti, M; Galluzzo, M; Botti, E; Vesa, Tc; Chimenti, S; Buzoianu, Ad; Costanzo, A | Articolo su rivista | |
1-gen-2013 | Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients | Talamonti, M; Galluzzo, M; Botti, E; Pavlidis, A; Spallone, G; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-mag-2013 | Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom | Boca, A; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, A; Costanzo., A | Intervento a convegno | |
1-ago-2013 | Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab | Talamonti, M; Botti, E; Galluzzo, M; Teoli, M; Spallone, G; Bavetta, M; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-gen-2014 | Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment | Talamonti, M; Galluzzo, M; Botti, E; Chimenti, S; Costanzo, A | Intervento a convegno | |
1-gen-2014 | What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice | Talamonti, M; Galluzzo, M; Bianchi, L; Boca, A; Costanzo, A; Chimenti, S | Articolo su rivista | |
1-gen-2015 | Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature | Chimenti, Ms; Talamonti, M; Novelli, L; Teoli, M; Galluzzo, M; Triggianese, P; Perricone, R | Articolo su rivista | |
1-gen-2015 | Linear psoriasis following the typical distribution of the sciatic nerve | Galluzzo, M; Talamonti, M; Di Stefani, A; Chimenti, S | Articolo su rivista | |
1-gen-2015 | HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients | Talamonti, M; Galluzzo, M; Botti, E; Costanzo, A; Chimenti, S | Intervento a convegno | |
1-gen-2016 | Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis | Talamonti, M; Galluzzo, M; Chimenti, S; Costanzo, A | Intervento a convegno | |
1-gen-2016 | HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up | Talamonti, M; Galluzzo, M; Chimenti, S; Costanzo, A | Articolo su rivista | |
1-gen-2016 | IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis | Galluzzo, M; Boca, An; Botti, E; Potenza, C; Malara, G; Malagoli, P; Vesa, S; Chimenti, S; Buzoianu, Ad; Talamonti, M; Costanzo, A | Articolo su rivista | |
1-gen-2016 | Tofacitinib for the treatment of psoriasis | Galluzzo, M; D'Adamio, S; Servoli, S; Bianchi, L; Chimenti, S; Talamonti, M | Articolo su rivista | |
1-gen-2016 | Brodalumab for the treatment of psoriasis | Galluzzo, M; D'Adamio, S; Bianchi, L; Talamonti, M | Articolo su rivista |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile